Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease

SAN DIEGO, May 15, 2013 (GLOBE NEWSWIRE) -- Receptos (Nasdaq:RCPT) today announced that Company personnel will deliver three scientific poster presentations about RPC1063 at the Digestive Disease Week (DDW) annual meeting from May 18 to 21, 2013 at the Orange County Convention Center in Orlando, Florida. DDW attracts thousands of physicians, researchers and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference. RPC1063 is the Company's lead sphingosine 1- phosphate 1 receptor (S1P1R) selective modulator in Phase 2 development for both ulcerative colitis (UC) and relapsing multiple sclerosis (RMS).

Receptos will present two abstracts on Saturday, May 18, 2013. The first Receptos abstract, titled, "Results of a safety and tolerability study of RPC1063, a novel orally administered sphingosine-1-phosphate receptor 1 (S1P1R) agonist, in healthy adult volunteers," discusses the emerging favorable safety, pharmacokinetic (PK) and pharmacodynamic (PD) profile for RPC1063 in support of the ongoing Phase 2 clinical development program in UC.

The second Receptos abstract, titled, "RPC1063, a potent, selective S1P1 receptor modulator, is active in therapeutic inflammatory bowel disease models and exhibits favorable PK/PD properties in healthy volunteers," elucidates the potential profile of RPC1063 as a potent and selective S1P1R modulator, with attractive clinical PK features including short half-life to facilitate rapid lymphocyte recovery.

Receptos will present a third abstract on Tuesday, May 21, titled, "RPC1063 is a potent S1P1R modulator with efficacy in the SAMP1/YitFc ileitis model: new evidence for dysregulation of S1P metabolism in preclinical models and patients with inflammatory bowel disease." This abstract discusses a possible contributory role of sphingosine 1- phosphate (S1P) at sites of inflammation within the intestine of UC patients. This finding is reproducible in animal models of IBD and may further support the mechanism by which an S1P1R modulator would play a therapeutic role in the treatment of IBD. These data were generated in collaboration with the laboratory of Jesus Rivera-Nieves, MD, from the University of California, San Diego.

RPC1063 is a novel, differentiated S1P1R selective modulator exhibiting picomolar potency that is effective in rodent models of both MS and IBD, and possesses an attractive safety profile in non-clinical toxicology studies. Receptos completed a Phase 1 study with RPC1063 which tested single ascending doses, multiple ascending doses and dose titration regimens in healthy volunteers. The Phase 1 results confirmed desirable PK, PD and safety features, which provide support for the differentiation strategy for RPC1063 as a potential best-in-class second-generation S1P1R modulator. Receptos is currently testing RPC1063 in a Phase 2 study for UC and a Phase 2/3 study for RMS.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is an S1P1R small molecule modulator candidate for immune indications, including RMS and IBD. The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

Forward-Looking Statements

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "anticipates," "estimates," "may," "could," "intends," "emerging, "elucidates," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements that are not strictly historical statements, including, without limitation, statements regarding the development of Receptos' lead product candidate, RPC1063, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements are based upon Receptos' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in additional detail in Receptos' SEC filings. All forward-looking statements contained in this release speak only as of the date on which they were made. Receptos undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708

Source:Receptos, Inc.